MI HB5845

Separates manufacturing licensing fees from other controlled substance licenses under part 73, establishing distinct fee structures with a $10.00 application fee and $75.00 annual license fee for manufacturers.

Authorizes the Department of Insurance and Financial Services to increase per-year license fees for manufacturers by rulemaking to cover actual costs of implementing the prescription drug cost and affordability review act.

Directs revenue from manufacturer license fee increases to be deposited into the prescription drug affordability fund established under the prescription drug cost and affordability review act.

Makes multiple technical amendments to replace "shall" with "must" in existing fund management provisions for the health professions regulatory fund, nurse professional fund, and pain management education fund.

Conditions bill's effectiveness on enactment of Senate Bill No. ____ or House Bill No. 5842 (the prescription drug cost and affordability review act).